Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Liabilities

The The Liabilities of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 30, 2026 is 7.83 B CNY. In the previous year, The Liabilities was 8.53 B CNY — a change of -8.22% (lower).

Liabilities

7.83 BCNY

YoY

-8.22%

Last updated:

In 2025, Harbin Pharmaceutical Group Co's total liabilities amounted to 7.83 B CNY, a -8.22% difference from the 8.53 B CNY total liabilities in the previous year.

The Harbin Pharmaceutical Group Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
5.62 B CNY
Jan 1, 2019
6.56 B CNY
Jan 1, 2020
7.86 B CNY
Jan 1, 2021
8.42 B CNY
Jan 1, 2022
8.48 B CNY
Jan 1, 2023
8.69 B CNY
Jan 1, 2024
8.53 B CNY
Jan 1, 2025
7.83 B CNY
The Harbin Pharmaceutical Group Co Liabilities history
YEARLiabilitiesYoY
7.83 BCNY-8.22%
8.53 BCNY-1.87%
8.69 BCNY+2.41%
8.48 BCNY+0.75%
8.42 BCNY+7.16%
7.86 BCNY+19.81%
6.56 BCNY+16.72%
5.62 BCNY-9.61%
6.22 BCNY-7.95%
6.75 BCNY+7.51%
6.28 BCNY-15.92%
7.47 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Harbin Pharmaceutical Group Co's Liabilities

Harbin Pharmaceutical Group Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Harbin Pharmaceutical Group Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Harbin Pharmaceutical Group Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Harbin Pharmaceutical Group Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Harbin Pharmaceutical Group Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

The Liabilities of Harbin Pharmaceutical Group Co is 7.83 B CNY in 2025.

The Liabilities of Harbin Pharmaceutical Group Co changed from 8.53 B CNY to 7.83 B CNY, representing a -8.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Harbin Pharmaceutical Group Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Harbin Pharmaceutical Group Co